| CR/CRu ≥ 12 months (n = 10) | CR/CRu < 12 months (n = 9) | P value |
---|---|---|---|
Male sex, n (%) | 7 (70) | 5 (56) | .65 |
Median age, years (range) | 61.5 (47–78) | 57.0 (37–74) | .43 |
ECOG performance status, n (%) | |||
  0 | 3 (30) | 4 (44) | .57 |
  1 | 6 (60) | 3 (33) | |
  2 | 1 (10) | 2 (22) | |
IPI score, n (%) | |||
  < 2 | 2 (20) | 1 (11) | 1.00 |
  ≥ 2 | 8 (80) | 8 (89) | |
Prior systemic therapies, n (%) | |||
  1 | 2 (20) | 3 (33) | .38 |
  2 | 3 (30) | 3 (33) | |
  3 | 0 | 2 (22) | |
  4 | 3 (30) | 1 (11) | |
  > 4 | 2 (20) | 0 | |
Best response to most recent prior therapy, n (%) | |||
  CR/CRu/PR | 2 (20) | 6 (67) | .07 |
  < PR | 8 (80) | 3 (33) | |
Disease stage at diagnosis, n (%) | |||
  I/II | 0 (0) | 4 (44) | .03 |
  III/IV | 10 (100) | 5 (56) | |
PTCL subtype, n (%) | |||
  PTCL-NOS | 5 (50) | 5 (56) | .34 |
  AITL | 4 (40) | 1 (11) | |
  ALK-1–negative ALCL | 1 (10) | 3 (33) | |
Bone marrow involvement, n (%) | 5 (50) | 2 (22) | .35 |
Elevated LDH, n (%) | 5 (50) | 8 (89) | .14 |
Platelet count x 109/L, median (range) | 199 (101–307) | 172 (99–649) | .42 |